...Treatment for the Reality of Depression” ). Kineta raises $5M in private round Immunotherapy company Kineta Inc....
...funding round led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio...

...Sante et de la Recherche Medicale (INSERM) University of Helsinki Howard Hughes Medical Institute Merck & Co. Inc. Pfizer Inc. Kineta Inc. DEAD...

...fever. GeoVax Labs Inc. has GEO-LM01 , a vaccine against Lassa fever, in preclinical testing. Kineta Inc....

...induces apoptosis of tumor cells while sparing normal bystanders. Kineta Immuno-Oncology LLC, a subsidiary of Kineta Inc....
...Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Elizabeth S. Eaton CRS-207 Keytruda RGT100 SD-101 Aduro Biotech Inc. Dynavax Technologies Corp. Kineta Inc. Merck...

...normal bystanders (see BioCentury Innovations, July 28, 2016) . Kineta Immuno-Oncology LLC, a subsidiary of Kineta Inc....

...LHF-535 , a small molecule antiviral with activity against Lassa virus and other arenaviruses from Kineta Inc....
...is also in preclinical development (see BioCentury Innovations, June 30, 2016) . Elizabeth S. Eaton GEO-LM01 LHF-535 GeoVax Labs Inc. Kineta Inc. Orgentec...

...the synthetic RIG-I agonist ImOI100 (RGT100) in Phase I/II testing for lymphoma and solid tumors. Kineta Inc....

...an award of up to £5 million ($6.7 million) from the Wellcome Trust in May, Kineta Inc....
...arenaviruses as a class. Kineta has not disclosed the compound's molecular target. On April 22, Kineta...
...instead in-licensed from Siga Technologies Inc. (NASDAQ:SIGA). Iadonato said the Wellcome Trust award should allow Kineta...

...dalazatide showed an improvement in Psoriasis Area and Severity Index (PASI) score at day 32. Kineta...
...analysis of blood and skin biopsies from patients in the trial are expected this quarter. Kineta...
...under a 2009 deal (see BioCentury, July 13, 2009). Airmid Inc. , Redwood City, Calif. Kineta Inc....

...Phase Ib data reported last week for Kineta Inc .'s dalazatide gave the first clinical evidence...
...the target lesion and looking at what is happening to it over time," he said. Kineta...
...less likely to cause immunosuppression than therapies that universally suppress T cell activity. He said Kineta...